Ignite Creation Date:
2024-05-05 @ 9:23 PM
Last Modification Date:
2024-10-26 @ 10:03 AM
Study NCT ID:
NCT00871455
Status:
COMPLETED
Last Update Posted:
2012-04-02
First Post:
2009-03-26
Brief Title:
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Insulin-like growth factor I IGF-I is used as a measure of the bodys ability to produce growth hormone Growth hormone is important for muscle tissue as well as many other tissues in the body Growth hormone GH and IGF-I have been shown to be reduced in many persons with SCI Baclofen is a FDA approved drug that is used to treat spasticity Persons receiving long-term baclofen therapy have been demonstrated to have increased growth hormone and IGF-I levels IGF-I levels will be determined before and after treatment with baclofen In this study the investigators will determine the minimum dose of baclofen at which improvements in GH and IGF-1 levels occur
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None